Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Battle of the Brits: BMJ, Lancet Continue Sniping Over Statins

Todd Neale

September 19, 2016

News Daily News

Neighborhood Access to Healthy Food Affects Residents’ Risk of Atherosclerosis

Leah Lawrence

August 22, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Daily News

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Michael O'Riordan

December 08, 2015

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Daily News

ROTAXUS Published: Rotational Atherectomy Does Not Increase DES Efficacy

Yael L. Maxwell

December 27, 2012

Advertisement

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Battle of the Brits: BMJ, Lancet Continue Sniping Over Statins

Neighborhood Access to Healthy Food Affects Residents’ Risk of Atherosclerosis

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

ROTAXUS Published: Rotational Atherectomy Does Not Increase DES Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content